Bayer appoints Tara Frenkl as new head of oncology development at oncology strategic business unit
Berlin: Bayer has announced Tara Frenkl, MD, MPH as the new Head of Oncology Development at its Oncology Strategic Business Unit, effective April 25, 2022.
She will report to Christine Roth, Head of the Oncology Strategic Business Unit at the company's Pharmaceuticals Division. Prior to joining Bayer, she held the role of Senior Vice President, Head of Medicine Development Leaders in Oncology at GlaxoSmithKline, with strategic impact on the global development of medicines across the company's Oncology portfolio.
"We are pleased to welcome Tara as the new Head of Oncology Development. Her broad experience, passion and dedication go hand in hand with Bayer`s commitment to put patients at the center of it all. It is important that we stay focused on the science coupled with speed and innovation to help bring new medications and indications as quickly as possible," said Christine Roth. "Tara`s leadership style is characterized by expertise and innovative thinking. She brings experience from all aspects of research and development, including clinical development, regulatory and global development strategy."
Prior to joining GlaxoSmithKline, Tara Frenkl was at Merck & Co., Inc. for 13 years in roles of increasing responsibility.
Read also: Odisha: Bayer launches 500 LPM oxygen plant in Rairakhol hospital
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.
Next Story
